HomeBUSINESS
BUSINESS

Mitsubishi Tanabe to Focus on US Approval for VLP Seasonal Flu Vaccine; Aims at 100 Billion Yen Sales for Vaccine Business by FY2030
(Oct.24.2017)

Seiichi Murakami, head of Ikuyaku Integrated Value Development Division
Mitsubishi Tanabe Pharma plans to allocate resources on a priority basis to a seasonal influenza vaccine currently in a PIII clinical study in the US and Canada, and will do its utmost to obtain early approval in the US. The company aims to grow its vaccine business from 38.9 billion yen in FY2016 to 100 billion yen by FY2030 ...
(LOG IN FOR FULL STORY)

News Calendar